These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 37104673)

  • 1. Advances in engineering and delivery strategies for cytokine immunotherapy.
    Bohmer M; Xue Y; Jankovic K; Dong Y
    Expert Opin Drug Deliv; 2023 May; 20(5):579-595. PubMed ID: 37104673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine engineering for targeted cancer immunotherapy.
    Bonati L; Tang L
    Curr Opin Chem Biol; 2021 Jun; 62():43-52. PubMed ID: 33684633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering cytokines for cancer immunotherapy: a systematic review.
    Fu Y; Tang R; Zhao X
    Front Immunol; 2023; 14():1218082. PubMed ID: 37483629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity.
    Shen S; Sckisel G; Sahoo A; Lalani A; Otter DD; Pearson J; DeVoss J; Cheng J; Casey SC; Case R; Yang M; Low R; Daris M; Fan B; Agrawal NJ; Ali K
    Front Immunol; 2020; 11():832. PubMed ID: 32457754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revitalizing Cytokine-Based Cancer Immunotherapy through Advanced Delivery Systems.
    Chen P; Paraiso WKD; Cabral H
    Macromol Biosci; 2023 Dec; 23(12):e2300275. PubMed ID: 37565723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-cytokine fusion proteins for cancer immunotherapy: an update on recent developments.
    Müller D
    BioDrugs; 2014 Apr; 28(2):123-31. PubMed ID: 24018469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
    Xiang J
    Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity.
    Neri D
    Cancer Immunol Res; 2019 Mar; 7(3):348-354. PubMed ID: 30824549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.
    Young PA; Morrison SL; Timmerman JM
    Semin Oncol; 2014 Oct; 41(5):623-36. PubMed ID: 25440607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation.
    Murer P; Neri D
    N Biotechnol; 2019 Sep; 52():42-53. PubMed ID: 30991144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering interferons and interleukins for cancer immunotherapy.
    Holder PG; Lim SA; Huang CS; Sharma P; Dagdas YS; Bulutoglu B; Sockolosky JT
    Adv Drug Deliv Rev; 2022 Mar; 182():114112. PubMed ID: 35085624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-cytokine fusion proteins.
    Kontermann RE
    Arch Biochem Biophys; 2012 Oct; 526(2):194-205. PubMed ID: 22445675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-cytokine fusion proteins for improving efficacy and safety of cancer therapy.
    Valedkarimi Z; Nasiri H; Aghebati-Maleki L; Majidi J
    Biomed Pharmacother; 2017 Nov; 95():731-742. PubMed ID: 28888210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoengineering approaches for cytokine therapy.
    Mansurov A; Lauterbach A; Budina E; Alpar AT; Hubbell JA; Ishihara J
    Am J Physiol Cell Physiol; 2021 Aug; 321(2):C369-C383. PubMed ID: 34232748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Facts and Hopes on Chimeric Cytokine Agents for Cancer Immunotherapy.
    Ren Z; Zhang X; Fu YX
    Clin Cancer Res; 2024 May; 30(10):2025-2038. PubMed ID: 38190116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody fusions with immunomodulatory proteins for cancer therapy.
    Müller D
    Pharmacol Ther; 2015 Oct; 154():57-66. PubMed ID: 26145167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine-based Cancer Immunotherapy: Challenges and Opportunities for IL-10.
    Rallis KS; Corrigan AE; Dadah H; George AM; Keshwara SM; Sideris M; Szabados B
    Anticancer Res; 2021 Jul; 41(7):3247-3252. PubMed ID: 34230118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facts and Hopes: Immunocytokines for Cancer Immunotherapy.
    Pabani A; Gainor JF
    Clin Cancer Res; 2023 Oct; 29(19):3841-3849. PubMed ID: 37227449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy.
    Huang P; Wang X; Liang X; Yang J; Zhang C; Kong D; Wang W
    Acta Biomater; 2019 Feb; 85():1-26. PubMed ID: 30579043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.